Mineralys publishes Phase 2 Explore-CKD data for lorundrostat
Mineralys Therapeutics has announced the publication of full results from its Phase 2 Explore-CKD trial in the journal Kidney International, offering the first peer-reviewed dataset for lorundrostat in patients with uncontrolled hypertension and chronic kidney disease (CKD).
The randomised, double-blind, placebo-controlled crossover trial enrolled 59 participants across 42 US sites. Patients were required to have stage 1 to 3b CKD, elevated urinary albumin-to-creatinine ratio (UACR between 200 and 5,000 mg/g) and uncontrolled blood pressure despite existing treatment with an ACE inhibitor or angiotensin receptor blocker plus an SGLT2 inhibitor. The mean baseline systolic blood pressure was 149 mmHg; 64% of participants were already taking three or more antihypertensive medicines, and 76% had type 2 diabetes.
Trial results
The primary endpoint, change in automated office systolic blood pressure at four weeks, was met with statistical significance. Lorundrostat 25 mg once daily produced a 9.3 mmHg reduction compared with 1.8 mmHg for placebo, yielding a placebo-adjusted reduction of 7.5 mmHg (95% CI: -12.3 to -2.7; p=0.0024). Diastolic blood pressure fell by a further 3.9 mmHg with the active drug versus 1.4 mmHg with placebo.
Beyond blood pressure, the data show meaningful effects on markers of kidney damage. UACR fell by 30.5% from baseline with lorundrostat, translating to a placebo-adjusted reduction of 25.6% (p=0.0015). Significant placebo-adjusted reductions were also seen in 24-hour UACR (26.1%; p less than 0.0001) and 24-hour urine protein-to-creatinine ratio (22.1%; p=0.0002). Serum aldosterone declined by 41.5% with lorundrostat versus a 1.8% increase with placebo. Importantly, no clinically meaningful change in serum cortisol was observed, consistent with lorundrostat's claimed high selectivity for aldosterone synthase over cortisol synthase.
Matthew Weir, Director of the Division of Nephrology at the University of Maryland Medical Center and lead author of the publication, said: "The Explore-CKD results demonstrate that lorundrostat may help CKD patients reduce otherwise uncontrolled high blood pressure and potentially improve their kidney function."
Market context and regulatory path
The aldosterone synthase inhibitor (ASI) class is attracting significant industry attention as a mechanistically distinct approach to resistant and uncontrolled hypertension. Dysregulated aldosterone is estimated to contribute to roughly 30% of all hypertensive cases, a population poorly served by existing renin-angiotensin-aldosterone system (RAAS) agents. AstraZeneca's baxdrostat, a rival ASI, has also reported Phase 2 data in resistant hypertension, making the class competitive at an early stage. The addition of proteinuria endpoints to lorundrostat's dataset is a meaningful differentiator if the renal signal holds in longer-term data, given that albuminuria reduction is increasingly valued by regulators as a surrogate endpoint in CKD trials following the FDA's 2023 guidance on accelerated approval pathways for kidney disease.
Mineralys says longer-term data from Explore-CKD participants who enrolled in the Transform-HTN open-label extension study will follow. The company has also completed the Phase 3 Launch-HTN registrational trial and the Phase 2 Advance-HTN study in uncontrolled and resistant hypertension more broadly, with an NDA acknowledged as having been accepted by the FDA. Investors will be watching the FDA review timeline closely, particularly given the company's forward-looking disclosures around potential agency funding and staffing constraints. The Explore-CKD publication strengthens the mechanistic and clinical rationale for lorundrostat's renal label expansion ambitions, but the four-week crossover design limits conclusions about durability of kidney protection.